You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The test will be designed to run on a portable device that can ultimately be rolled out to point-of-need settings such as doctors' offices and workplaces.
The firm expects to launch a tissue-based immunohistochemistry version of the test, which detects QSOX1, in mid-2021, followed by a dipstick plasma-based assay by early 2022.
The new method uses Takara Bio's SmartChip PCR instrument, chips, and reagents to run 5,184 reactions per chip in less than 30 minutes.
A comprehensive study of genomics malpractice lawsuits showed only a modest increase in recent years, but ASU’s Marchant wouldn't bet on it staying this way in the long term.
The Biomedical Advanced Research and Development Authority aims to produce at least two US Food and Drug Administration-cleared tests.
In order to raise the profile of diagnostics in healthcare, Aspinall thinks the foundational knowledge about the industry needs to be improved through education.